Vanda Pharmaceuticals (VNDA) Competitors $4.36 -0.08 (-1.80%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends VNDA vs. IRWD, EBS, CDXS, RIGL, XOMA, VSTM, SGMO, LXRX, ACHV, and RGLSShould you be buying Vanda Pharmaceuticals stock or one of its competitors? The main competitors of Vanda Pharmaceuticals include Ironwood Pharmaceuticals (IRWD), Emergent BioSolutions (EBS), Codexis (CDXS), Rigel Pharmaceuticals (RIGL), XOMA (XOMA), Verastem (VSTM), Sangamo Therapeutics (SGMO), Lexicon Pharmaceuticals (LXRX), Achieve Life Sciences (ACHV), and Regulus Therapeutics (RGLS). These companies are all part of the "biotechnology" industry. Vanda Pharmaceuticals vs. Ironwood Pharmaceuticals Emergent BioSolutions Codexis Rigel Pharmaceuticals XOMA Verastem Sangamo Therapeutics Lexicon Pharmaceuticals Achieve Life Sciences Regulus Therapeutics Vanda Pharmaceuticals (NASDAQ:VNDA) and Ironwood Pharmaceuticals (NASDAQ:IRWD) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, community ranking, valuation, earnings, risk and dividends. Does the media favor VNDA or IRWD? In the previous week, Ironwood Pharmaceuticals had 4 more articles in the media than Vanda Pharmaceuticals. MarketBeat recorded 9 mentions for Ironwood Pharmaceuticals and 5 mentions for Vanda Pharmaceuticals. Ironwood Pharmaceuticals' average media sentiment score of 0.64 beat Vanda Pharmaceuticals' score of -0.10 indicating that Ironwood Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vanda Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Ironwood Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, VNDA or IRWD? Vanda Pharmaceuticals has a beta of 0.77, meaning that its stock price is 23% less volatile than the S&P 500. Comparatively, Ironwood Pharmaceuticals has a beta of 0.34, meaning that its stock price is 66% less volatile than the S&P 500. Do analysts prefer VNDA or IRWD? Vanda Pharmaceuticals currently has a consensus price target of $15.50, indicating a potential upside of 255.50%. Ironwood Pharmaceuticals has a consensus price target of $10.40, indicating a potential upside of 184.15%. Given Vanda Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Vanda Pharmaceuticals is more favorable than Ironwood Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vanda Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Ironwood Pharmaceuticals 0 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Which has stronger valuation and earnings, VNDA or IRWD? Vanda Pharmaceuticals has higher earnings, but lower revenue than Ironwood Pharmaceuticals. Ironwood Pharmaceuticals is trading at a lower price-to-earnings ratio than Vanda Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVanda Pharmaceuticals$192.64M1.32$2.51M-$0.28-15.57Ironwood Pharmaceuticals$442.73M1.32-$1.00B-$0.03-122.00 Does the MarketBeat Community favor VNDA or IRWD? Vanda Pharmaceuticals received 28 more outperform votes than Ironwood Pharmaceuticals when rated by MarketBeat users. Likewise, 66.34% of users gave Vanda Pharmaceuticals an outperform vote while only 61.08% of users gave Ironwood Pharmaceuticals an outperform vote. CompanyUnderperformOutperformVanda PharmaceuticalsOutperform Votes53866.34% Underperform Votes27333.66% Ironwood PharmaceuticalsOutperform Votes51061.08% Underperform Votes32538.92% Do insiders & institutionals have more ownership in VNDA or IRWD? 88.1% of Vanda Pharmaceuticals shares are held by institutional investors. 8.9% of Vanda Pharmaceuticals shares are held by insiders. Comparatively, 12.9% of Ironwood Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Is VNDA or IRWD more profitable? Ironwood Pharmaceuticals has a net margin of -0.65% compared to Vanda Pharmaceuticals' net margin of -8.59%. Ironwood Pharmaceuticals' return on equity of -0.96% beat Vanda Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Vanda Pharmaceuticals-8.59% -3.02% -2.52% Ironwood Pharmaceuticals -0.65%-0.96%0.74% SummaryIronwood Pharmaceuticals beats Vanda Pharmaceuticals on 10 of the 18 factors compared between the two stocks. Get Vanda Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for VNDA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VNDA vs. The Competition Export to ExcelMetricVanda PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$268.22M$6.36B$5.24B$8.95BDividend YieldN/A2.94%5.13%4.04%P/E Ratio-15.579.8589.6417.34Price / Sales1.32315.001,254.2378.66Price / CashN/A61.4443.8235.97Price / Book0.466.055.324.79Net Income$2.51M$154.90M$122.69M$225.00M7 Day Performance-5.22%-1.70%-0.16%1.52%1 Month Performance-4.18%2.72%3.75%4.68%1 Year Performance18.16%2.83%27.41%20.89% Vanda Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VNDAVanda Pharmaceuticals3.8895 of 5 stars$4.36-1.8%$15.50+255.5%+16.0%$268.22M$192.64M-15.57290IRWDIronwood Pharmaceuticals4.4292 of 5 stars$3.64-8.1%$10.40+185.7%-70.4%$582.50M$378.42M-121.33220Short Interest ↓News CoverageEBSEmergent BioSolutions4.2396 of 5 stars$9.26-6.3%$14.33+54.8%+415.9%$501.74M$1.09B-2.261,600Analyst UpgradeCDXSCodexis3.9716 of 5 stars$4.46+1.6%$8.33+86.8%+86.6%$362.95M$64.45M-5.13250Short Interest ↑News CoverageRIGLRigel Pharmaceuticals4.0471 of 5 stars$16.76+3.1%$36.20+116.0%+49.1%$295.23M$157.47M119.72160Analyst ForecastShort Interest ↑Analyst RevisionNews CoverageGap UpXOMAXOMA4.18 of 5 stars$24.08-4.4%$81.50+238.5%+38.4%$283.74M$9.71M-6.9210Analyst UpgradeVSTMVerastem2.7429 of 5 stars$5.25-8.4%$13.38+154.8%-52.0%$233.66M$10M-1.6550SGMOSangamo Therapeutics2.8109 of 5 stars$1.10-5.6%$5.50+400.0%+145.2%$229.51M$52.29M-1.47480LXRXLexicon Pharmaceuticals1.746 of 5 stars$0.70-9.2%$6.00+762.1%-49.6%$171.38M$5.23M-0.93140ACHVAchieve Life Sciences1.5991 of 5 stars$3.34-1.2%$14.80+343.1%-28.5%$114.86MN/A-2.9620Short Interest ↑News CoverageRGLSRegulus Therapeutics2.3442 of 5 stars$1.31-6.9%$10.80+723.1%+9.7%$85.94MN/A-1.2330Insider TradePositive NewsGap Down Related Companies and Tools Related Companies Ironwood Pharmaceuticals Competitors Emergent BioSolutions Competitors Codexis Competitors Rigel Pharmaceuticals Competitors XOMA Competitors Verastem Competitors Sangamo Therapeutics Competitors Lexicon Pharmaceuticals Competitors Achieve Life Sciences Competitors Regulus Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:VNDA) was last updated on 1/18/2025 by MarketBeat.com Staff From Our PartnersURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredThe Biggest Money-Making Idea in My 43 Years in the Stock MarketBillionaires and top investors - including the late great Charlie Munger - and many more names you would recog...The Oxford Club | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementThe #1 Coin Poised to Soar Under Trump Pro-Crypto White House could make this the investment opportunity of...Crypto 101 Media | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vanda Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vanda Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VNDA Stock Alerts